{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:06:42Z","timestamp":1771034802529,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11010-022-04576-0","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:26:59Z","timestamp":1665404819000},"page":"1013-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Developing therapeutic approaches for chronic myeloid leukemia: a review"],"prefix":"10.1007","volume":"478","author":[{"given":"Veerandra","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Jyotirmayee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"4576_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, Kumar V, Gupta SK, Kumari G, Verma M (2021) Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review. Med Oncol 38:1\u201316. https:\/\/doi.org\/10.1007\/s12032-021-01462-5","journal-title":"Med Oncol"},{"key":"4576_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2019.00665","volume":"9","author":"PE Westerweel","year":"2019","unstructured":"Westerweel PE, Te Boekhorst PA, Levin M-D, Cornelissen JJ (2019) New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol 9:665. https:\/\/doi.org\/10.3389\/fonc.2019.00665","journal-title":"Front Oncol"},{"key":"4576_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV (2015) Natural course and biology of CML. Ann Hematol 94:107\u2013121. https:\/\/doi.org\/10.1007\/s00277-015-2325-z","journal-title":"Ann Hematol"},{"issue":"5","key":"4576_CR4","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5):1517\u201336","journal-title":"Blood"},{"key":"4576_CR5","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127. https:\/\/doi.org\/10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"4576_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0971-6866.86198","volume":"17","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Madkaikar M, Ghosh K, Vundinti BR (2011) Deletion of ABL\/BCR on der (9) associated with severe basophilia. Indian J Hum Genet 17:100. https:\/\/doi.org\/10.4103\/0971-6866.86198","journal-title":"Indian J Hum Genet"},{"key":"4576_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz JL, Le Coutre P, Paquette R, Chuah C, Nicolini F, Apperley J, Khoury H, Talpaz M (2013) A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias. N Engl J Med 369:1783\u20131796. https:\/\/doi.org\/10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"key":"4576_CR8","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4187","journal-title":"Cancer Res"},{"issue":"2","key":"4576_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE (2009) Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control: J Moffitt Cancer Center 16(2):122\u2013131. https:\/\/doi.org\/10.1177\/107327480901600204","journal-title":"Cancer Control: J Moffitt Cancer Center"},{"key":"4576_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000336610","volume":"127","author":"L Nardinelli","year":"2012","unstructured":"Nardinelli L, Sanabani SS, Didone A, de Barros FP, Serpa M, Novaes MMY, Marchiani M, Ruiz AL, Lima IS, Chamone DdAF (2012) Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematol v Acta Haematol 127:228\u2013234. https:\/\/doi.org\/10.1159\/000336610","journal-title":"Acta Haematol v Acta Haematol"},{"key":"4576_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Br\u00fcmmendorf TH (2014) Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol 11:89\u201399. https:\/\/doi.org\/10.1016\/j.ddtec.2014.03.003","journal-title":"Drug Discov Today Technol"},{"key":"4576_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong A (2017) Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 8:469. https:\/\/doi.org\/10.3389\/fimmu.2017.00469","journal-title":"Front Immunol"},{"issue":"7","key":"4576_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/15680096113139990088","volume":"13","author":"GV Helgason","year":"2013","unstructured":"Helgason GV, Mukhopadhyay A, Karvela M, Salomoni P, Calabretta B, Holyoake TL (2013) Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets 13(7):724\u2013734. https:\/\/doi.org\/10.2174\/15680096113139990088","journal-title":"Curr Cancer Drug Targets"},{"key":"4576_CR14","doi-asserted-by":"crossref","unstructured":"Palam\u00e0 IE, Leporatti S, Luca Ed, Renzo ND, Maffia M, Gambacorti-Passerini C, Rinaldi R, Gigli G, Cingolani R and Coluccia AM (2010). Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine 5:419\u2013431","DOI":"10.2217\/nnm.10.8"},{"key":"4576_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121:396\u2013409. https:\/\/doi.org\/10.1172\/JCI35721","journal-title":"J Clin Invest"},{"key":"4576_CR16","first-page":"362","volume-title":"The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?","author":"BZ Carter","year":"2010","unstructured":"Carter BZ, Mak DH, Cortes J, Andreeff M (2010) The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol Elsevier, Amsterdam, pp 362\u2013370"},{"key":"4576_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14737140.2014.864562","volume":"14","author":"L Bergmann","year":"2014","unstructured":"Bergmann L, Maute L, Guschmann M (2014) Temsirolimus for advanced renal cell carcinoma. Expert Rev Anticancer Ther 14:9\u201321","journal-title":"Expert Rev Anticancer Ther"},{"key":"4576_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.seminhematol.2010.06.006","volume":"7","author":"W Zhao","year":"2017","unstructured":"Zhao W, Qiu Y, Kong D (2017) Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta pharm sin B 7:27\u201337. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.006","journal-title":"Acta pharm sin B"},{"key":"4576_CR19","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1158\/1538-7445.AM2018-5802","volume":"78","author":"N Owusu-Brackett","year":"2018","unstructured":"Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Meric-Bernstam F (2018) Efficacy of PI3K\u03b2 inhibitor AZD8186 in PTEN-deficient triple-negative breast cancer. Cancer Res 78:5802\u20135802. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-5802","journal-title":"Cancer Res"},{"key":"4576_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/CAD.0b013e32834c8683","volume":"23","author":"P Baumann","year":"2012","unstructured":"Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R (2012) Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 23:131\u2013138. https:\/\/doi.org\/10.1097\/CAD.0b013e32834c8683","journal-title":"Anticancer Drugs"},{"key":"4576_CR21","doi-asserted-by":"publisher","first-page":"79842","DOI":"10.18632\/oncotarget.13035","volume":"7","author":"C Simioni","year":"2016","unstructured":"Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM (2016) Synergistic effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway or NUP214-ABL1 fusion protein in human acute lymphoblastic leukemia. Oncotarget 7:79842. https:\/\/doi.org\/10.18632\/oncotarget.13035","journal-title":"Oncotarget"},{"key":"4576_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12079-020-00558-3","volume":"14","author":"Z-J Li","year":"2020","unstructured":"Li Z-J, Hou Y-J, Hao G-P, Pan X-X, Fei H-R, Wang F-Z (2020) CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. J Cell Commun Signal 14:377\u2013387. https:\/\/doi.org\/10.1007\/s12079-020-00558-3","journal-title":"J Cell Commun Signal"},{"key":"4576_CR23","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1535-7163.mct-16-0602-t","volume":"16","author":"GS Roth","year":"2017","unstructured":"Roth GS, Macek Jilkova Z, Zeybek Kuyucu A, Kurma K, Ahmad Pour ST, Abbadessa G, Yu Y, Busser B, Marche PN, Leroy V (2017) Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinomaARQ 092 in DEN-induced hepatocellular carcinoma. Mol Cancer Ther 16:2157\u20132165. https:\/\/doi.org\/10.1158\/1535-7163.mct-16-0602-t","journal-title":"Mol Cancer Ther"},{"key":"4576_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-CT024","author":"S Pant","year":"2018","unstructured":"Pant S, Subbiah V, Rodon J, Janku F, Hong D, Karp D, Piha-Paul S, Tsimberidou AM, Naing A, Fu S (2018) Abstract CT024: results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT024","journal-title":"Cancer Res"},{"key":"4576_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1158\/1078-0432.CCR-16-0226","volume":"23","author":"B Jin","year":"2017","unstructured":"Jin B, Wang C, Li J, Du X, Ding K, Pan J (2017) Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1\/\u03b2-catenin and eradicates leukemia stem cells in chronic myelogenous leukemiap65\/FOXM1\/\u03b2-catenin in CML stem cells. Clin Cancer Res 23:789\u2013803. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0226","journal-title":"Clin Cancer Res"},{"key":"4576_CR26","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120:2254\u20132264. https:\/\/doi.org\/10.1172\/JCI41246","journal-title":"J Clin Invest"},{"key":"4576_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/leu.2008.262","volume":"23","author":"Y Hu","year":"2009","unstructured":"Hu Y, Chen Y, Douglas L, Li S (2009) \u03b2-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 23:109\u2013116. https:\/\/doi.org\/10.1038\/leu.2008.262","journal-title":"Leukemia"},{"key":"4576_CR28","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA (2010) The Wnt\/\u03b2-catenin pathway is required for the development of leukemia stem cells in AML. Science 327:1650\u20131653. https:\/\/doi.org\/10.1126\/science.1186624","journal-title":"Science"},{"key":"4576_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T (2007) Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer cell 12:528\u2013541. https:\/\/doi.org\/10.1016\/j.ccr.2007","journal-title":"Cancer cell"},{"key":"4576_CR30","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2012-11-465161","volume":"121","author":"EW Petersdorf","year":"2013","unstructured":"Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T (2013) Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. Blood J Am Soc Hematol 121:1896\u20131905. https:\/\/doi.org\/10.1182\/blood-2012-11-465161","journal-title":"Blood J Am Soc Hematol"},{"key":"4576_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/724360","author":"A Hamad","year":"2013","unstructured":"Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R (2013) Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int. https:\/\/doi.org\/10.1155\/2013\/724360","journal-title":"Stem Cells Int"},{"key":"4576_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clml.2018.03.007","volume":"18","author":"A Dehghanifard","year":"2018","unstructured":"Dehghanifard A, Kaviani S, Abroun S, Mehdizadeh M, Saiedi S, Maali A, Ghaffari S, Azad M (2018) Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin Lymphoma Myeloma Leuk 18:311\u2013320. https:\/\/doi.org\/10.1016\/j.clml.2018.03.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4576_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clml.2011.10.003","volume":"12","author":"T Al Baghdadi","year":"2012","unstructured":"Al Baghdadi T, Abonour R, Boswell HS (2012) Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma Leuk 12:94\u2013105. https:\/\/doi.org\/10.1016\/j.clml.2011.10.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4576_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/leu.2008.392","volume":"23","author":"I Bruns","year":"2009","unstructured":"Bruns I, Czibere A, Fischer J, Roels F, Cadeddu R, Buest S, Bruennert D, Huenerlituerkoglu A, Stoecklein N, Singh R (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23:892\u2013899. https:\/\/doi.org\/10.1038\/leu.2008.392","journal-title":"Leukemia"},{"key":"4576_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O\u2019Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D (2010) Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer cell 18:74\u201387. https:\/\/doi.org\/10.1016\/j.ccr.2010.04.025","journal-title":"Cancer cell"},{"key":"4576_CR36","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.3390\/ijms20225616","volume":"20","author":"F Muselli","year":"2019","unstructured":"Muselli F, Peyron J-F, Mary D (2019) Druggable biochemical pathways and potential therapeutic alternatives to target leukemic stem cells and eliminate the residual disease in chronic myeloid leukemia. Int J Mol Sci 20:5616. https:\/\/doi.org\/10.3390\/ijms20225616","journal-title":"Int J Mol Sci"},{"key":"4576_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2015.03.005","volume":"361","author":"J Shou","year":"2015","unstructured":"Shou J, Jing J, Xie J, You L, Jing Z, Yao J, Han W, Pan H (2015) Nuclear factor of activated T cells in cancer development and treatment. Cancer lett 361:174\u2013184. https:\/\/doi.org\/10.1016\/j.canlet.2015.03.005","journal-title":"Cancer lett"},{"key":"4576_CR38","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/cells9092114","volume":"9","author":"D Doheny","year":"2020","unstructured":"Doheny D, Manore SG, Wong GL, Lo H-W (2020) Hedgehog signaling and truncated GLI1 in cancer. Cells 9:2114. https:\/\/doi.org\/10.3390\/cells9092114","journal-title":"Cells"},{"key":"4576_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/35077219","volume":"411","author":"J Taipale","year":"2001","unstructured":"Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411:349\u2013354. https:\/\/doi.org\/10.1038\/35077219","journal-title":"Nature"},{"key":"4576_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/cells7110208","volume":"7","author":"IN Sari","year":"2018","unstructured":"Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY (2018) Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. Cells 7:208. https:\/\/doi.org\/10.3390\/cells7110208","journal-title":"Cells"},{"key":"4576_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.phrs.2019.02.027","volume":"142","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee S, Sil PC (2019) Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharmacol Res 142:251\u2013261. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.027","journal-title":"Pharmacol Res"},{"key":"4576_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.exphem.2012.01.003","volume":"40","author":"W Su","year":"2012","unstructured":"Su W, Meng F, Huang L, Zheng M, Liu W, Sun H (2012) Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through \u03b2-catenin signaling. Exp Hematol 40:418\u2013427. https:\/\/doi.org\/10.1016\/j.exphem.2012.01.003","journal-title":"Exp Hematol"},{"key":"4576_CR43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458:776\u2013779. https:\/\/doi.org\/10.1038\/nature07737","journal-title":"Nature"},{"key":"4576_CR44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-013-0045-z","volume":"73","author":"JM Ruch","year":"2013","unstructured":"Ruch JM, Kim EJ (2013) Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs 73:613\u2013623. https:\/\/doi.org\/10.1007\/s40265-013-0045-z","journal-title":"Drugs"},{"key":"4576_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/17460441.2017.1303477","volume":"12","author":"GA Horne","year":"2017","unstructured":"Horne GA, Copland M (2017) Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opin Drug Discov 12:465\u2013474. https:\/\/doi.org\/10.1080\/17460441.2017.1303477","journal-title":"Expert Opin Drug Discov"},{"key":"4576_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/SCCAA.S58613","volume":"8","author":"V Campbell","year":"2015","unstructured":"Campbell V, Copland M (2015) Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning 8:27\u201332. https:\/\/doi.org\/10.2147\/SCCAA.S58613","journal-title":"Stem Cells Cloning"},{"key":"4576_CR47","doi-asserted-by":"publisher","first-page":"2749173","DOI":"10.1155\/2019\/2749173","volume":"2019","author":"Q-Y Sun","year":"2019","unstructured":"Sun Q-Y, Zhou H-H, Mao X-Y (2019) Emerging roles of 5-lipoxygenase phosphorylation in inflammation and cell death. Oxid Med Cell Longev 2019:2749173. https:\/\/doi.org\/10.1155\/2019\/2749173","journal-title":"Oxid Med Cell Longev"},{"key":"4576_CR48","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1002\/jcp.30301","volume":"236","author":"D Ma","year":"2021","unstructured":"Ma D, Liu P, Wang P, Zhou Z, Fang Q, Wang J (2021) PKC-\u03b2\/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia. J Cell Physiol 236:6312\u20136327. https:\/\/doi.org\/10.1002\/jcp.30301","journal-title":"J Cell Physiol"},{"key":"4576_CR49","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las RJ, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers 13:4820. https:\/\/doi.org\/10.3390\/cancers13194820","journal-title":"Cancers"},{"key":"4576_CR50","doi-asserted-by":"publisher","first-page":"43662","DOI":"10.18632\/oncotarget.18216","volume":"8","author":"M Chen","year":"2017","unstructured":"Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X (2017) Targeting BCR-ABL + stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget 8:43662. https:\/\/doi.org\/10.18632\/oncotarget.18216","journal-title":"Oncotarget"},{"key":"4576_CR51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbrc.2017.06.051","volume":"490","author":"M Dolinska","year":"2017","unstructured":"Dolinska M, Piccini A, Wong WM, Gelali E, Johansson A-S, Klang J, Xiao P, Yektaei-Karin E, Str\u00f6mberg UO, Mustjoki S (2017) Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+ CD38\u2212 stem and progenitor cells in chronic myeloid leukemia. Biochem Biophys Res Commun 490:378\u2013384. https:\/\/doi.org\/10.1016\/j.bbrc.2017.06.051","journal-title":"Biochem Biophys Res Commun"},{"key":"4576_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12612","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhao H, Luo J, Liao Y, Tan K, Hu G (2021) A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro. Oncology lett 21:1\u201310. https:\/\/doi.org\/10.3892\/ol.2021.12612","journal-title":"Oncology lett"},{"key":"4576_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/sctm.17-0175","volume":"7","author":"E Arrigoni","year":"2018","unstructured":"Arrigoni E, Del Re M, Galimberti S, Restante G, Rofi E, Crucitta S, Barat\u00e8 C, Petrini M, Danesi R, Di Paolo A (2018) Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment. Stem Cells Transl Med 7:305\u2013314. https:\/\/doi.org\/10.1002\/sctm.17-0175","journal-title":"Stem Cells Transl Med"},{"key":"4576_CR54","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"J Rawlings","year":"2004","unstructured":"Rawlings J, Rosler KM, Harrison DA (2004) The JAK\/STAT signaling pathway. J Cell Sci 117:1281\u20131283. https:\/\/doi.org\/10.1242\/jcs.00963","journal-title":"J Cell Sci"},{"key":"4576_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00024382-200202000-00001","volume":"17","author":"RN Cooney","year":"2002","unstructured":"Cooney RN (2002) Suppressors of cytokine signaling (SOCS): inhibitors of the JAK\/STAT pathway. Shock 17:83\u201390. https:\/\/doi.org\/10.1097\/00024382-200202000-00001","journal-title":"Shock"},{"key":"4576_CR56","volume-title":"Novel antagonists of the SH2 domain of GRB2 decrease chronic myeloid leukemia (CML) cell proliferation via the JAK\/STAT pathway, dissertation","author":"S Aguiar","year":"2019","unstructured":"Aguiar S (2019) Novel antagonists of the SH2 domain of GRB2 decrease chronic myeloid leukemia (CML) cell proliferation via the JAK\/STAT pathway, dissertation. California State University, Chico"},{"key":"4576_CR57","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2019-125595","volume":"134","author":"A Trojani","year":"2019","unstructured":"Trojani A, Pungolino E, Rossi G, D\u2019adda M, Bossi LE, Baruzzo G, Di Camillo B, Perego A, Turrini M, Elena C (2019) Progressive down regulation of JAK-STAT, cell cycle, and ABC transporter genes in CD34+\/Lin-cells of chronic-phase chronic myeloid leukemia (CP-CML) patients at diagnosis Vs 12 Months of nilotinib treatment vs healthy subjects. Blood 134:5034. https:\/\/doi.org\/10.1182\/blood-2019-125595","journal-title":"Blood"},{"key":"4576_CR58","doi-asserted-by":"publisher","first-page":"102750","DOI":"10.1016\/j.autrev.2021.102750","volume":"20","author":"E Favoino","year":"2021","unstructured":"Favoino E, Prete M, Catacchio G, Ruscitti P, Navarini L, Giacomelli R, Perosa F (2021) Working and safety profiles of JAK\/STAT signaling inhibitors. Are these small molecules also smart? Autoimmun Rev 20:102750. https:\/\/doi.org\/10.1016\/j.autrev.2021.102750","journal-title":"Autoimmun Rev"},{"key":"4576_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S L\u00fc","year":"2014","unstructured":"L\u00fc S, Wang J (2014) Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol 7:1\u201310. https:\/\/doi.org\/10.1186\/1756-8722-7-2","journal-title":"J Hematol Oncol"},{"key":"4576_CR60","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou A-C, Craig AR, Michallet M, Nicolini FE (2012) Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120:2573\u20132580. https:\/\/doi.org\/10.1182\/blood-2012-03-415307","journal-title":"Blood"},{"key":"4576_CR61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/17474086.2016.1151351","volume":"9","author":"Y Rosshandler","year":"2016","unstructured":"Rosshandler Y, Shen AQ, Cortes J, Khoury HJ (2016) Omacetaxine mepesuccinate for chronic myeloid leukemia. Expert Rev Hematol 9:419\u2013424. https:\/\/doi.org\/10.1586\/17474086.2016.1151351","journal-title":"Expert Rev Hematol"},{"key":"4576_CR62","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1080\/10428194.2017.1283030","volume":"58","author":"A Maiti","year":"2017","unstructured":"Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O\u2019Brien S, Kantarjian H (2017) Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma 58:2240\u20132242. https:\/\/doi.org\/10.1080\/10428194.2017.1283030","journal-title":"Leuk Lymphoma"},{"key":"4576_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02902-2","volume":"11","author":"M Zhu","year":"2020","unstructured":"Zhu M, Gong Z, Wu Q, Su Q, Yang T, Yu R, Xu R, Zhang Y (2020) Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated \u03b2-catenin loss in hepatocellular carcinoma. Cell Death Dis 11:1\u201313. https:\/\/doi.org\/10.1038\/s41419-020-02902-2","journal-title":"Cell Death Dis"},{"key":"4576_CR64","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.bcp.2021.114538","volume":"188","author":"F Wang","year":"2021","unstructured":"Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, Wang F, Naren D, Cui Y, Liu X (2021) Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. Biochem Pharmacol 188:114538. https:\/\/doi.org\/10.1016\/j.bcp.2021.114538","journal-title":"Biochem Pharmacol"},{"key":"4576_CR65","first-page":"381","volume":"12","author":"D Ramchandran","year":"2020","unstructured":"Ramchandran D, Kethipalli A, Krishnamurthy M (2020) Bio-analytical method development and validation of daunorubicin and cytarabine in rat plasma by LC-MS\/MS and its application in pharmacokinetic studies. J Pharm Sci Res 12:381\u2013386","journal-title":"J Pharm Sci Res"},{"key":"4576_CR66","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2007-08-107482","volume":"111","author":"W Deenik","year":"2008","unstructured":"Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ (2008) Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 111:2581\u20132588. https:\/\/doi.org\/10.1182\/blood-2007-08-107482","journal-title":"Blood"},{"key":"4576_CR67","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","volume":"102","author":"M Gardembas","year":"2003","unstructured":"Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N (2003) Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102:4298\u20134305. https:\/\/doi.org\/10.1182\/blood-2003-04-1010","journal-title":"Blood"},{"key":"4576_CR68","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-013-1730-4","volume":"92","author":"N Thielen","year":"2013","unstructured":"Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg J, Kersten MJ, Sinnige HA (2013) High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Ann Hematol 92:1049\u20131056. https:\/\/doi.org\/10.1007\/s00277-013-1730-4","journal-title":"Ann Hematol"},{"key":"4576_CR69","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","volume":"35","author":"F Guilhot","year":"2021","unstructured":"Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler A-P, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A (2021) Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia 35:2332\u20132345. https:\/\/doi.org\/10.1038\/s41375-020-01117-w","journal-title":"Leukemia"},{"key":"4576_CR70","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/08880018.2020.1767244","volume":"37","author":"MA Wajid","year":"2020","unstructured":"Wajid MA, Gupta AK, Das G, Sahoo D, Meena JP, Seth R (2020) Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine. Pediatr Hematol Oncol 37:573\u2013581. https:\/\/doi.org\/10.1080\/08880018.2020.1767244","journal-title":"Pediatr Hematol Oncol"},{"key":"4576_CR71","doi-asserted-by":"publisher","first-page":"7753857","DOI":"10.1155\/2021\/7753857","volume":"2021","author":"S Kapor","year":"2021","unstructured":"Kapor S, \u010coki\u0107 V, Santibanez JF (2021) Mechanisms of hydroxyurea-induced cellular senescence: an oxidative stress connection? Oxid Med Cell Longev 2021:7753857. https:\/\/doi.org\/10.1155\/2021\/7753857","journal-title":"Oxid Med Cell Longev"},{"key":"4576_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2174\/1574892811666160926143534","volume":"11","author":"M Iman","year":"2016","unstructured":"Iman M, Khansefid Z, Davood A (2016) Modeling and proposed molecular mechanism of hydroxyurea through docking and molecular dynamic simulation to curtail the action of ribonucleotide reductase. Recent Pat Anticancer Drug Discov 11:461\u2013468. https:\/\/doi.org\/10.2174\/1574892811666160926143534","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"4576_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0858-1","author":"X Huang","year":"2021","unstructured":"Huang X, Ma T, Zhu Y, Jiao B, Yu S, Wang K, Mi J-Q, Ren R (2021) IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia. Front Med. https:\/\/doi.org\/10.1007\/s11684-021-0858-1","journal-title":"Front Med"},{"issue":"2","key":"4576_CR74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21276\/sjpm.2019.4.2.15","volume":"4","author":"A Singh","year":"2019","unstructured":"Singh A, Kulshrestha AR, Singh SK, Kulshrestha MR (2019) To study the clinical and haematological profile of cml patients and to compare the haematological response of imatinib and hydroxyurea in different subsets of CML patients. Saudi J Pathol Microbiol 4(2):127\u2013133. https:\/\/doi.org\/10.21276\/sjpm.2019.4.2.15","journal-title":"Saudi J Pathol Microbiol"},{"key":"4576_CR75","doi-asserted-by":"crossref","unstructured":"Dimou M, Panayiotidis P (2014) Tyrosine kinase inhibitors and interferon. Mediterranean Journal of Hematology and Infectious Diseases. Mediterr J Hematol Infect Dis 6(1):e2014006","DOI":"10.4084\/mjhid.2014.006"},{"issue":"7","key":"4576_CR76","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","volume":"114","author":"M Talpaz","year":"1991","unstructured":"Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 114(7):532\u20138. https:\/\/doi.org\/10.7326\/0003-4819-114-7-532","journal-title":"Ann Intern Med"},{"key":"4576_CR77","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1172\/JCI3094","volume":"102","author":"MY Gordon","year":"1998","unstructured":"Gordon MY, Marley SB, Lewis JL, Davidson RJ, Nguyen DX, Grand FH, Amos TA, Goldman JM (1998) Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 102:710\u2013715. https:\/\/doi.org\/10.1172\/JCI3094","journal-title":"J Clin Invest"},{"key":"4576_CR78","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","volume":"104","author":"M Baccarani","year":"2004","unstructured":"Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D (2004) Imatinib and pegylated human recombinant interferon-\u03b12b in early chronic-phase chronic myeloid leukemia. Blood 104:4245\u20134251. https:\/\/doi.org\/10.1182\/blood-2004-03-0826","journal-title":"Blood"},{"key":"4576_CR79","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","volume":"95","author":"F Palandri","year":"2010","unstructured":"Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M (2010) The response to imatinib and interferon-\u03b1 is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 95:1415. https:\/\/doi.org\/10.3324\/haematol.2009.021246","journal-title":"Haematologica"},{"key":"4576_CR80","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markev\u00e4rn B, Remes K, Stentoft J, Almqvist A, Bj\u00f6reman M, Flogeg\u00e5rd M, Koskenvesa P, Lindblom A (2011) Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia. Blood 118:3228\u20133235. https:\/\/doi.org\/10.1182\/blood-2011-02-336685","journal-title":"Blood"},{"issue":"1","key":"4576_CR81","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","volume":"2","author":"FE Nicolini","year":"2015","unstructured":"Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P (2015) Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol 2(1):e37-46. https:\/\/doi.org\/10.1016\/S2352-3026(14)00027-1","journal-title":"Lancet Haematol"},{"key":"4576_CR82","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/leu.2016.121","volume":"30","author":"H Hjorth-Hansen","year":"2016","unstructured":"Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, H\u00f6glund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX (2016) Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia 30:1853\u20131860. https:\/\/doi.org\/10.1038\/leu.2016.121","journal-title":"Leukemia"},{"key":"4576_CR83","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang K-D, Snyder DS, Huettner CS, Shultz L, Holyoake T (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer cell 17:427\u2013442. https:\/\/doi.org\/10.1016\/j.ccr.2010.03.011","journal-title":"Cancer cell"},{"key":"4576_CR84","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 9:603. https:\/\/doi.org\/10.3389\/fonc.2019.00603","journal-title":"Front Oncol"},{"key":"4576_CR85","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/2040620717719851","volume":"8","author":"AE Eskazan","year":"2017","unstructured":"Eskazan AE, Keskin D (2017) Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol 8:237\u2013243. https:\/\/doi.org\/10.1177\/2040620717719851","journal-title":"Ther Adv Hematol"},{"key":"4576_CR86","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bjh.16381","volume":"189","author":"YR Do","year":"2020","unstructured":"Do YR, Kwak JY, Kim JA, Kim HJ, Chung JS, Shin HJ, Kim SH, Bunworasate U, Choi CW, Zang DY (2020) Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol 189:303\u2013312. https:\/\/doi.org\/10.1111\/bjh.16381","journal-title":"Br J Haematol"},{"key":"4576_CR87","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11899-021-00658-w","volume":"16","author":"N Javidi-Sharifi","year":"2021","unstructured":"Javidi-Sharifi N, Hobbs G (2021) Future directions in chronic phase CML treatment. Curr Hematol Malig Rep 16:500\u2013508. https:\/\/doi.org\/10.1007\/s11899-021-00658-w","journal-title":"Curr Hematol Malig Rep"},{"key":"4576_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2020-141268","volume":"136","author":"M Lu","year":"2020","unstructured":"Lu M, Deng C, Xiong Y, Wang H, Xu P, Men L, Xie T, Jiang Q, Chen Z, Niu Q (2020) Exposure-response (ER) analysis of olverembatinib (HQP1351) in Chinese patients with chronic myeloid leukemia (CML). Blood 136:5\u20136. https:\/\/doi.org\/10.1182\/blood-2020-141268","journal-title":"Blood"},{"key":"4576_CR89","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2021-152693","volume":"138","author":"EJ Jabbour","year":"2021","unstructured":"Jabbour EJ, Kantarjian H, Issa GC, Beck JT, Klisovic RB, Mukherjee S, Oehler VG, Chen Z, Lu M, Fu T (2021) Trial in progress: phase 1b bridging study of the pharmacokinetics (PK), safety, and efficacy of orally administered olverembatinib (HQP1351) in patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 138:2551\u20132551. https:\/\/doi.org\/10.1182\/blood-2021-152693","journal-title":"Blood"},{"key":"4576_CR90","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142142","volume":"136","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, Huang X, Chen Z, Niu Q, Shi D, Li Z, Hou Y, Hu Y, Li W, Liu X (2020) Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase II) trials. Blood 136:50\u201351","journal-title":"Blood"},{"issue":"24","key":"4576_CR91","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh Y-T, Talpaz M, Hochhaus A (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326. https:\/\/doi.org\/10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"issue":"431\u2013443","key":"4576_CR92","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Stevens SLS, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD (2019) Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36(431\u2013443):e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.004","journal-title":"Cancer Cell"},{"key":"4576_CR93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143816","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S, Turkina AG, Kim D-W, Apperley J, Cortes JE (2020) Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with\u2265 2 tyrosine kinase inhibitors TKIs. Blood. https:\/\/doi.org\/10.1182\/blood-2020-143816","journal-title":"Blood"},{"key":"4576_CR94","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","volume":"14","author":"S Malik","year":"2021","unstructured":"Malik S, Hassan S, E\u015fkazan AE (2021) Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Rev Hematol 14:975\u2013978. https:\/\/doi.org\/10.1080\/17474086.2021.1990034","journal-title":"Expert Rev Hematol"},{"key":"4576_CR95","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2019-127951","volume":"134","author":"AG Turkina","year":"2019","unstructured":"Turkina AG, Vinogradova O, Lomaia E, Shatokhina E, Shukhov OA, Chelysheva EY, Shikhbabaeva D, Nemchenko I, Petrova A, Bykova A (2019) PF-114: a 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia including BCRABL1 T315I. Blood 134:1638. https:\/\/doi.org\/10.1182\/blood-2019-127951","journal-title":"Blood"},{"key":"4576_CR96","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood.V122.21.3907.3907","volume":"122","author":"A Mian","year":"2013","unstructured":"Mian A, Rafiei A, Metodieva A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Stroganov O, Novikov F, Ottmann OG (2013) PF-114, a novel selective Pan BCR\/ABL inhibitor targets the T315I and suppress models of advanced Ph+ ALL. Blood 122:3907. https:\/\/doi.org\/10.1182\/blood.V122.21.3907.3907","journal-title":"Blood"},{"key":"4576_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01087-x","volume":"23","author":"M Shoukier","year":"2021","unstructured":"Shoukier M, Kubiak M, Cortes J (2021) Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Curr Oncol Rep 23:1\u20138. https:\/\/doi.org\/10.1007\/s11912-021-01087-x","journal-title":"Curr Oncol Rep"},{"key":"4576_CR98","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138:2042\u20132050. https:\/\/doi.org\/10.1182\/blood.2021012082","journal-title":"Blood"},{"key":"4576_CR99","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","volume":"6","author":"P Carpinelli","year":"2007","unstructured":"Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158\u20133168. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0444","journal-title":"Mol Cancer Ther"},{"key":"4576_CR100","doi-asserted-by":"publisher","first-page":"e19164","DOI":"10.1371\/journal.pone.0019164","volume":"6","author":"S Balabanov","year":"2011","unstructured":"Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I (2011) Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PloS ONE 6:e19164. https:\/\/doi.org\/10.1371\/journal.pone.0019164","journal-title":"PloS ONE"},{"key":"4576_CR101","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500\u2013502. https:\/\/doi.org\/10.1182\/blood-2006-05-025049","journal-title":"Blood"},{"key":"4576_CR102","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1124\/dmd.107.015438","volume":"35","author":"JE Ballard","year":"2007","unstructured":"Ballard JE, Prueksaritanont T, Tang C (2007) Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase. Drug Metab Dispos 35:1447\u20131451. https:\/\/doi.org\/10.1124\/dmd.107.015438","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"4576_CR103","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1124\/dmd.110.032326","volume":"38","author":"A Gong","year":"2010","unstructured":"Gong A, Chen X, Deng P, Zhong D (2010) Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos 38(8):1328\u20131340. https:\/\/doi.org\/10.1124\/dmd.110.032326","journal-title":"Drug Metab Dispos"},{"issue":"17","key":"4576_CR104","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1080\/00397910903289248","volume":"40","author":"G Xu","year":"2010","unstructured":"Xu G, Shen H, Tong T, Lu A, Gou S (2010) Synthesis, crystal structure, and spectral characterization of flumatinib mesylate. Synth Commun 40(17):2564\u20132570. https:\/\/doi.org\/10.1080\/00397910903289248","journal-title":"Synth Commun"},{"issue":"1","key":"4576_CR105","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","volume":"27","author":"L Zhang","year":"2021","unstructured":"Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Wang J (2021) Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd studyphase III study of flumatinib versus imatinib for CML-CP. Clin Cancer Res 27(1):70\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1600","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4576_CR106","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00280-020-04117-w","volume":"86","author":"Y Kuang","year":"2020","unstructured":"Kuang Y, Song HL, Yang GP, Pei Q, Yang XY, Ye L, Huang J (2020) Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects. Cancer Chemother Pharmacol 86(3):339\u2013346. https:\/\/doi.org\/10.1007\/s00280-020-04117-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"4576_CR107","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","volume":"15","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2022","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Breccia M, Jabbour E, Mauro M, Cortes JE (2022) A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol 15:90. https:\/\/doi.org\/10.1186\/s13045-022-01309-0","journal-title":"J Hematol Oncol"},{"key":"4576_CR108","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/01.HS9.0000849852.81498.42","volume":"6","author":"Y Gu","year":"2022","unstructured":"Gu Y, Song C, Ge Z (2022) PB1749: apoptotic effect of flumatinib combined with BCL2 inhibitor on PH+ B-cell acute lymphoblastic leukemia. HemaSphere 6:1630\u20131631","journal-title":"HemaSphere"},{"key":"4576_CR109","doi-asserted-by":"publisher","first-page":"106337","DOI":"10.1016\/j.leukres.2020.106337","volume":"91","author":"N\u00d6 Yurtta\u015f","year":"2020","unstructured":"Yurtta\u015f N\u00d6, E\u015fkazan AE (2020) Novel therapeutic approaches in chronic myeloid leukemia. Leuk Res 91:106337. https:\/\/doi.org\/10.1016\/j.leukres.2020.106337","journal-title":"Leuk Res"},{"key":"4576_CR110","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2076669","author":"U Y\u0131lmaz","year":"2022","unstructured":"Y\u0131lmaz U, Bulan B, Belli \u00c7, E\u015fkazan AE (2022) Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review. Expert Rev Hematol. https:\/\/doi.org\/10.1080\/17474086.2022.2076669","journal-title":"Expert Rev Hematol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04576-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T17:11:06Z","timestamp":1682356266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04576-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04576-0","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article does not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}